Fiscal 2023 Outlook
The Company is providing initial guidance ranges for net sales and adjusted EBITDA1, as follows:
Net sales
$900-$925 million
Adjusted EBITDA
$130-$135
Omega Therapeutics Inc (NASDAQ: OMGA) announced preliminary data from the initial two dose level cohorts (n=8) from Part 1 of its Phase 1/2 MYCHELANGELO I study of OTX-2002 in hepatocellular carcinoma and other solid tumors associated
Mental healthcare biotech company advancing psilocybin therapy COMPASS Pathways plc (NASDAQ: CMPS) reported its financial results for the first quarter 2023 ended March 31, 2023 and updated on recent business and clinical progresses.
In numbers: